Aurinia Pharmaceuticals (NASDAQ:AUPH) Announces Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP announced its earnings results on Monday. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.08, Zacks reports. The company had revenue of $62.47 million during the quarter, compared to analyst estimates of $61.06 million. Aurinia Pharmaceuticals had a negative net margin of 10.23% and a negative return on equity of 4.41%. Aurinia Pharmaceuticals updated its FY 2025 guidance to EPS.

Aurinia Pharmaceuticals Price Performance

NASDAQ:AUPH traded up $0.04 during trading hours on Friday, hitting $8.19. 1,590,708 shares of the stock traded hands, compared to its average volume of 1,334,970. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals has a 1 year low of $5.11 and a 1 year high of $10.67. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -54.60 and a beta of 1.16. The stock has a 50 day moving average price of $8.02 and a 200 day moving average price of $8.24.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, March 27th.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, CFO Joseph M. Miller sold 61,859 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $494,872.00. Following the transaction, the chief financial officer now owns 633,515 shares of the company's stock, valued at $5,068,120. The trade was a 8.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Peter Greenleaf sold 195,593 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the transaction, the chief executive officer now directly owns 1,953,892 shares in the company, valued at $15,631,136. This represents a 9.10% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 343,898 shares of company stock valued at $2,753,094 over the last 90 days. 4.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Several large investors have recently added to or reduced their stakes in AUPH. Royal Bank of Canada lifted its holdings in Aurinia Pharmaceuticals by 65.3% during the first quarter. Royal Bank of Canada now owns 367,661 shares of the biotechnology company's stock valued at $2,956,000 after purchasing an additional 145,179 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Aurinia Pharmaceuticals by 8.7% in the first quarter. AQR Capital Management LLC now owns 503,543 shares of the biotechnology company's stock worth $4,048,000 after buying an additional 40,380 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Aurinia Pharmaceuticals by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,811 shares of the biotechnology company's stock worth $642,000 after buying an additional 3,497 shares in the last quarter. Hedge funds and other institutional investors own 36.83% of the company's stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.